Mentor, mother, activist, advocate, sister, survivor, researcher and Fred Hutch friend, Bridgette Hempstead died last month ...

The Head and Neck Radiation Oncology Group (GORTEC) announced significant improvement in disease-free survival for locally ...

Referring to cancer as a “battle” minimizes the many real issues faced by cancer patients who must live with nausea, pain, ...

In addition to using gemcitabine and the natural killer cells that are TGF-β imprinted, we also are combining an anti-GD2 antibody called naxitamab that's provided by Y-mAbs. Naxitamab, as I said, is ...

New study successfully made CTC-derived organoids from breast cancer patients' blood samples to investigate cell survival and ...

Mersana shares Phase 1 data on Emi-Le for TNBC and details FDA's Fast Track status for XMT-1660 in advanced HER2-low breast ...

Mersana Therapeutics (MRSN) stock hits a 52-week low in reaction to early clinical results for its cancer drug Emi-Le in ...

For female patients aged at least 66 years, odds of prevalent CVD up with locally advanced and metastatic disease.

TrialTranslator uses machine learning to assess cancer RCT generalizability, revealing survival gaps for high-risk patients ...

Arvinas (ARVN) announced updated guidance for the planned first- and second-line combination clinical trials for vepdegestrant in patients with ...

Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either ...

Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...